Adolfo Garcia-Sastre

Now we have some candidates.

Yeah, correct.

So phase one, the main thing that tells you is safety.

And the second thing I tell you, whether you get the immune response that you think is good for the vaccine.

In phase one, we got induction of antibodies at levels that we think they will be protective.

We have not been able to prove that in humans, but we think that the levels that we achieve, they will be protective.

Phase two, we have not started.

We have been in phase one.

Money, mainly money.

They are very costly.

And there was a NIH program that was called Civic that was for trying to get improved influenza vaccines.

We were part of this program, but this program has been stopped.

And right now it's unclear whether it's going to restart.

Well, it was not really a cut, but there has been also a lot of slowdown in finances from NIH.

So these contracts, they were supposed to, at one moment, bring clinical trials.

But because funding stopped it and there is no call for new proposals yet, and if a call comes...

because it takes time to review and then get funded, there's going to be at least a gap of one year or two years.

The problem with the vaccines that we are ready to go is that if they are not going, they need to maintain a stability program, and this costs money, money that we don't have.

So we are trying to find partners

outside NIH to finance for at least a stability program, or if not, also for some phase two, phase one clinical trials that we still need to do.